Bradley A. Bart
Articles
-
Apr 1, 2024 |
jacc.org | Alexander Peikert |Bradley A. Bart |Muthiah Vaduganathan |Brian Claggett
IntroductionBeta-blockers are cornerstone therapeutic agents for the management of heart failure with reduced ejection fraction (HFrEF). Conversely, high-quality randomized trial data on beta-blocker use among patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) remain sparse.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →